Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

OptimizeRx (OPRX) Operating Expenses (2016 - 2026)

OptimizeRx's Operating Expenses history spans 16 years, with the latest figure at $15.5 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 15.54% to $15.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $61.9 million, a 15.3% decrease, with the full-year FY2025 number at $61.9 million, down 15.3% from a year prior.
  • Operating Expenses hit $15.5 million in Q4 2025 for OptimizeRx, roughly flat from $15.5 million in the prior quarter.
  • Over the last five years, Operating Expenses for OPRX hit a ceiling of $28.7 million in Q4 2023 and a floor of $6.8 million in Q1 2021.
  • Historically, Operating Expenses has averaged $14.5 million across 5 years, with a median of $13.9 million in 2023.
  • Biggest five-year swings in Operating Expenses: surged 115.82% in 2023 and later crashed 36.03% in 2024.
  • Tracing OPRX's Operating Expenses over 5 years: stood at $11.8 million in 2021, then grew by 13.15% to $13.3 million in 2022, then soared by 115.82% to $28.7 million in 2023, then crashed by 36.03% to $18.4 million in 2024, then dropped by 15.54% to $15.5 million in 2025.
  • Business Quant data shows Operating Expenses for OPRX at $15.5 million in Q4 2025, $15.5 million in Q3 2025, and $15.4 million in Q2 2025.